Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins
Statins are promising for breast cancer therapy; dipyridamole can potentiate their effects, but is contraindicated in some cases. Here, the authors develop a pharmacogenomics pipeline to predict other compounds that potentiate statins, and validate the top candidates in cell line screens and 3D cult...
Main Authors: | Jenna E. van Leeuwen, Wail Ba-Alawi, Emily Branchard, Jennifer Cruickshank, Wiebke Schormann, Joseph Longo, Jennifer Silvester, Peter L. Gross, David W. Andrews, David W. Cescon, Benjamin Haibe-Kains, Linda Z. Penn, Deena M. A. Gendoo |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-10-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-33144-9 |
Similar Items
-
Pharmacogenomics Statins: Biomarkers for Clinical Prediction
by: Herni Suprapti
Published: (2018-09-01) -
The impact of violating the independence assumption in meta-analysis on biomarker discovery
by: Farnoosh Abbas-Aghababazadeh, et al.
Published: (2023-01-01) -
Pharmacogenomics of statin therapy: any new insights in efficacy or safety?
by: Hopewell, J, et al.
Published: (2014) -
Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing
by: William J. Canestaro, et al.
Published: (2012-10-01) -
When the same treatment has different response: The role of pharmacogenomics in statin therapy
by: Edward Zheng, et al.
Published: (2024-01-01)